Edmonton, AB (April 23, 2007) Edmonton, Canada’s sixth largest city, will stockpile COLD-fX® for frontline emergency workers as part of a broad pandemic preparedness plan, CV Technologies Inc. (TSX:CVQ) announced today.
“This is one more tool we can add to our pandemic preparedness toolkit,” said Bob Black, Director of Edmonton’s Office of Emergency Preparedness. “There are so many unknowns in planning for a possible pandemic that anything we can do to be prepared makes sense. As cities across North America consider the challenges associated with a pandemic, we need to take every reasonable precaution to help our emergency personnel stay on the job, so they can help others.”
The City of Edmonton has had a general public health emergency contingency plan in place since 2003 and has one full-time planner working strictly on pandemic preparedness. The plan includes:
• measures to protect City staff from the effects of the pandemic influenza;
• steps to maintain essential services during periods of staff shortages due to illness;
• support mechanisms for Edmonton’s Capital Health region during a pandemic.
As part of the Company’s social responsibility program, a $250,000 supply of COLD-fX will be made available to the City through a cost-sharing arrangement with CV Technologies, the makers of COLD-fX. The supply will be available for use by police, fire and emergency medical personnel – all key City employees.
“COLD-fX has potential to provide additional protection to front line workers,” said Dr. Jacqueline Shan, president, CEO and Chief Scientific Officer of CV Technologies. “Vaccines may also offer some protection. However current vaccines are not likely to be completely effective if a virus mutates, which is what medical experts fear might happen with the avian flu virus.” In addition, it takes between four to six months after the virus strikes to develop an effective vaccine, added Dr. Shan. “During this time, COLD-fX may help provide additional protection to front line workers by enhancing their immune systems.”
While COLD-fX has a five-year shelf life, CV Technologies has developed contingency plans to ensure that the City of Edmonton will always have access to a fresh supply of COLD-fX regardless of when it might decide to employ it.
- 30 -
About the City of Edmonton
Vibrant and culturally diverse, Edmonton is one of Canada’s most desired places to live, learn, work, invest and visit. Edmonton is a world leader in healthcare research and innovation, education, and environmental stewardship. Home to more than one million people and the global port to more than $100 billion in northern oil sands development, Alberta’s capital is an economic powerhouse offering a prime combination of business opportunity and quality of life.
About CV Technologies Inc.
CV Technologies, founded in 1992, is a global leader in the development and commercialization of naturally derived, evidence based, natural therapeutics for disease prevention and health maintenance. The Company's lead product - COLD-fX - strengthens the immune system and is widely used in Canada as a leading over the counter (OTC) remedy for preventing and relieving cold and flu infections. A comprehensive treatment claim approved by Health Canada for COLD-fX states that it “helps reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.” Comprehensive therapeutic claims require support by the highest level of scientific evidence: randomized, double-blind, placebo-controlled clinical trials. In the United States COLD-fX is marketed as an immune enhancing dietary supplement. COLD-fX, with its unique and patented mechanism of action was standardized according to the Company's ChemBioPrint (CBP) process. The CBP process precisely identifies the chemical profile and biological activity of multi-active compounds in evidence-based natural therapeutics. The CBP process also provides a manufacturing protocol that ensures each batch of the final product delivers verifiable and provable health benefits. International manufacturing, marketing, patents and trademarks are held by fX Life Sciences International GmbH. COLD-fX is distributed and sold in the U.S. by COLD-fX Pharmaceuticals (USA) Inc. Both companies are wholly-owned subsidiaries of CV Technologies Inc. fX Life Sciences International GmbH and COLD-fX Pharmaceuticals (USA) Inc. maintain a call center for product information: 1-877-490-3300.
This news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results or events to differ materially from the results or events predicted in this release, including those comments predicting the potential benefit of COLD-fX during a pandemic flu outbreak. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct and that the results, performance or achievements expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a more in-depth account of risks and uncertainties, please refer to documents filed with the Canadian securities regulatory authorities through the System for Electronic Document Analysis and Retrieval (SEDAR). Subject to its obligations under applicable law, the Company assumes no duty to update this disclosure. The Company is a 12g3-2(b) SEC registrant.